Dou Y, Xu K, Deng Y, Jia Z, Lan J, Xu X, et al. Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method. Antib Ther. 2023;6:76-86 pubmed publisher

Tan T, Mou Z, Lei R, Ouyang W, Yuan M, Song G, et al. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike. Nat Commun. 2023;14:2003 pubmed publisher

Vamva E, OZOG S, Leaman D, Yu Hong Cheng R, Irons N, Ott A, et al. A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin. Mol Ther Methods Clin Dev. 2023;28:366-384 pubmed publisher

Li M, Ren Y, Aw Z, Chen B, Yang Z, Lei Y, et al. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. Nat Commun. 2022;13:7957 pubmed publisher

Ouyang W, Tan T, Lei R, Song G, Kieffer C, Andrabi R, et al. Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning. Sci Adv. 2022;8:eadd7221 pubmed publisher

Peng L, Fang Z, Renauer P, McNamara A, Park J, Lin Q, et al. Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species. Cell Rep. 2022;40:111160 pubmed publisher

Fang Z, Peng L, Filler R, Suzuki K, McNamara A, Lin Q, et al. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nat Commun. 2022;13:3250 pubmed publisher

Liu C, Harn H, Chen K, Lee J, Lin S, Chiu T. Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidenephthalide in a Recurrent GBM. J Oncol. 2022;2022:3236058 pubmed publisher

Orvain C, Cauvet A, Prudent A, Guignabert C, Thuillet R, Ottaviani M, et al. Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. Arthritis Res Ther. 2022;24:13 pubmed publisher

Dehmani S, Nerrière Daguin V, Néel M, Elain Duret N, Heslan J, Belarif L, et al. SIRPγ-CD47 Interaction Positively Regulates the Activation of Human T Cells in Situation of Chronic Stimulation. Front Immunol. 2021;12:732530 pubmed publisher

Zhang Q, Ju B, Ge J, Chan J, Cheng L, Wang R, et al. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nat Commun. 2021;12:4210 pubmed publisher

Wang R, Zhang Q, Ge J, Ren W, Zhang R, Lan J, et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity. 2021;54:1611-1621.e5 pubmed publisher

Hu Q, Li H, Archibong E, Chen Q, Ruan H, Ahn S, et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat Biomed Eng. 2021;5:1038-1047 pubmed publisher

Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115-119 pubmed publisher

Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, et al. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. J Clin Invest. 2020;130:374-388 pubmed publisher